Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Differential effects of aspirin before and after diagnosis of colorectal cancer.

Pasche B.

JAMA. 2013 Jun 26;309(24):2598-9. doi: 10.1001/jama.2013.6600. No abstract available. Erratum in: JAMA. 2013 Jul 10;310(2):208.

PMID:
23800937
2.

Aspirin use and risk of colorectal cancer according to BRAF mutation status.

Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S.

JAMA. 2013 Jun 26;309(24):2563-71. doi: 10.1001/jama.2013.6599.

3.

KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.

Symvoulakis EK, Zaravinos A, Zoras O, Spandidos DA.

Int J Biol Markers. 2011 Oct-Dec;26(4):276-7. doi: 10.5301/JBM.2011.8874. No abstract available.

PMID:
22139644
4.

CANCER. Revisiting vitamin C and cancer.

Reczek CR, Chandel NS.

Science. 2015 Dec 11;350(6266):1317-8. doi: 10.1126/science.aad8671. No abstract available.

PMID:
26659042
5.

Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.

Rosty C, Williamson EJ, Clendenning M, Walters RJ, Walsh MD, Win AK, Jenkins MA, Hopper JL, Winship I, Southey MC, Giles GG, English DR, Buchanan DD.

J Natl Cancer Inst. 2014 Aug 11;106(8). pii: dju180. doi: 10.1093/jnci/dju180. Print 2014 Aug. No abstract available.

PMID:
25114271
6.

How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer.

Renaud S, Falcoz PE.

Future Oncol. 2015;11(15):2109-11. doi: 10.2217/fon.15.124. No abstract available.

PMID:
26235176
7.

BRAF-mutated metastatic colorectal cancer between past and future.

Cremolini C, Di Maio M, Petrelli F, Berenato R, Loupakis F, Pietrantonio F.

Br J Cancer. 2015 Dec 1;113(11):1634-5. doi: 10.1038/bjc.2015.316. Epub 2015 Sep 10. No abstract available.

8.

RAS mutations in colorectal cancer.

Sunakawa Y, Lenz HJ, Ichikawa W.

N Engl J Med. 2013 Nov 28;369(22):2159. doi: 10.1056/NEJMc1312697#SA1. No abstract available.

PMID:
24283233
9.

RAS mutations in colorectal cancer.

Douillard JY, Rong A, Sidhu R.

N Engl J Med. 2013 Nov 28;369(22):2159-60. doi: 10.1056/NEJMc1312697. No abstract available.

10.

[RAS testing in metastatic colorectal cancer].

Kirstein MM, Vogel A.

Z Gastroenterol. 2014 Sep;52(9):1095-6. doi: 10.1055/s-0034-1384878. Epub 2014 Sep 8. German. No abstract available.

PMID:
25198090
11.

EGFR signalling and oncogenic pathway signature in colorectal cancer.

Sahin IH, Oktay AA.

Gut. 2013 Nov;62(11):1670. doi: 10.1136/gutjnl-2013-304781. Epub 2013 Mar 26. No abstract available.

PMID:
23532175
12.

[Implementation of standard operation procedures for KRAS andBRAF gene mutation detection in colorectal cancer].

Yan L, Liu Y, Liu X, Xu F, Zhang K, Xu J, Li L.

Zhonghua Bing Li Xue Za Zhi. 2015 Jan;44(1):55-8. Chinese. No abstract available.

PMID:
25765033
13.

A biomarker for metastatic colorectal cancer and treatment goals.

Sudoyo AW.

Acta Med Indones. 2014 Apr;46(2):81-2. No abstract available.

14.

Response.

Lochhead P, Meyerhardt JA, Fuchs CS, Ogino S.

J Natl Cancer Inst. 2014 Aug 11;106(8). pii: dju181. doi: 10.1093/jnci/dju181. Print 2014 Aug. No abstract available.

PMID:
25114272
15.

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.

Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S.

J Clin Oncol. 2008 Sep 1;26(25):4217-9. doi: 10.1200/JCO.2008.18.7286. No abstract available.

PMID:
18757341
16.

KRAS genotypes and outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Zaccarelli E, Tomao S, Codacci-Pisanelli G.

JAMA. 2011 Feb 9;305(6):565-6; author reply 566. doi: 10.1001/jama.2011.87. No abstract available.

PMID:
21304079
17.

Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer.

Lipsyc MD, Yaeger R, Dengel LT, Saltz L.

JAMA Oncol. 2015 Aug;1(5):686-7. doi: 10.1001/jamaoncol.2015.0569. Review. No abstract available.

PMID:
26182332
18.

Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Brandi G, Biasco G, Tavolari S.

J Natl Cancer Inst. 2011 Aug 17;103(16):1278. doi: 10.1093/jnci/djr266. Epub 2011 Jul 20. No abstract available.

PMID:
21775746
19.

KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases.

Velho S, Oliveira C, Seruca R.

J Clin Oncol. 2009 Jan 1;27(1):158-9; author reply 159. doi: 10.1200/JCO.2008.20.1525. Epub 2008 Dec 1. No abstract available.

PMID:
19047277
20.

Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.

Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, Peters-Golden M, Rock CL, Boland CR, Brenner DE.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):447-53.

Supplemental Content

Support Center